Alzheimers Disease Clinical Trials

ReadTheTrial indexes 19 studies for Alzheimers Disease. The most common development stage is Phase 2 (7 trials). Each trial page translates ClinicalTrials.gov eligibility, outcomes, and design into patient-friendly language so you can compare options quickly.

19 clinical trials found for Alzheimers Disease.

Pipeline by Phase

PhaseTrialsDistribution
Phase 2 7
37%
Phase 3 6
32%
N/A 6
32%

Trial Status Breakdown

Trials for Alzheimers Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

NCT07399171 · NOT YET RECRUITING · Phase 2

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

NCT07170150 · RECRUITING · Phase 3

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

NCT07169578 · RECRUITING · Phase 3

A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

NCT07105709 · RECRUITING · Phase 2

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease

NCT06647498 · RECRUITING · Phase 3

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease

NCT05552157 · RECRUITING · Phase 3

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's Disease

NCT06384573 · ACTIVE NOT RECRUITING · Phase 3

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and Non-Amyloid Disease-Related Biomarkers Following Daily Oral Administration in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease

NCT06402838 · ACTIVE NOT RECRUITING · Phase 2

A Community-Based Screening Program to Identify, Using Blood-Based Biomarkers, Individuals With or Without Alzheimer's Disease Symptoms Who Are at High Risk for Brain Amyloid Pathology

NCT06043700 · ACTIVE NOT RECRUITING · N/A

A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants With Alzheimer's Disease

NCT05744401 · TERMINATED · Phase 2

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

NCT05269394 · ACTIVE NOT RECRUITING · Phase 3

A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050 · ACTIVE NOT RECRUITING · Phase 2

New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study - A Study to Improve Precision in Amyloid PET Coverage and Patient Care

NCT04426539 · COMPLETED · N/A

Detection of Alzheimer's Disease (AD)-Related Seeds as Biomarkers for Accurate Diagnosis of AD（AD-seeds-detector）

NCT04850053 · RECRUITING · N/A

Study on the Diagnostic Cut-off Value of Core Biomarkers in Cerebrospinal Fluid and Blood of Alzheimer's Disease

NCT05020106 · RECRUITING · N/A

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease

NCT02947893 · COMPLETED · Phase 2

Wake Forest Alzheimer's Disease Clinical Core

NCT03140865 · RECRUITING · N/A

A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

NCT01767311 · COMPLETED · Phase 2

Study of the Predictive Markers and the Pathophysiological Mechanisms of Alzheimer's Disease: Transverse and Longitudinal Approach in Anatomical and Functional Multimodal Imaging

NCT01638949 · COMPLETED · N/A

Frequently Asked Questions

What clinical trials are available for Alzheimers Disease?

There are 19 clinical trials listed for Alzheimers Disease. These span various phases from early safety studies to post-approval monitoring. Browse the trial listings below for details.

How do I find recruiting Alzheimers Disease trials?

Look for trials with "Recruiting" status in the listings below, or visit our recruiting page to filter by condition. Each trial page includes decoded eligibility criteria to help you determine if you qualify.

What phases are Alzheimers Disease trials in?

Current Alzheimers Disease trials are distributed across: Phase 2 (7), Phase 3 (6), N/A (6).

Find More Trials